The purpose of this study is to compare overall survival in patients treated with ipilimumab-nivolumab followed by either nivolumab or cabozantinib-nivolumab. You must be diagnosed with metastatic renal cell cancer.
Contact phoneTracy Bellefeuil | 517.364.2835
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryMetastatic Renal Cell